Luke Ralston, a biomedical engineer and scientific reviewer at the FDA, has emphasised the need for transparency in AI regulation. The two main issues hampering the regulation are performance drift and data generalisation. Ralston stated that AI companies need to start monitoring and tracking the performance of their products once deployed and they also need to expand its representative data to cover more than just the demographics.
MacOS Malware Poses as Unarchiver App to Steal User Data
Well, cyber friends! You won’t believe what we just uncovered on our daily hunt for all things security-related here at the Bay Area cyberhawks HQ.